Coya Therapeutics, Inc.
COYANASDAQHealthcare● Active
$4.55
+$0.13(+2.94%)
Market Cap$82849822
P/E Ratio—
52W High$7.75
52W Low$3.71
Coya Therapeutics, Inc. (COYA) · Income Statement
Annual, quarterly, or TTM views · SEC 10-K & 10-Q via FMP · adjust period and M/B/T below.
FMP · COYA · as of 2026-06-09
Financial statements
Revenue · Gross Profit · Net Income
| Breakdown | 2025-12 | 2024-12 | 2023-12 | 2022-12 | 2021-12 |
|---|---|---|---|---|---|
| Revenue | |||||
| Revenue | $7.95M | $3.55M | $6.00M | $0.00M | $0.00M |
| Cost of Revenue | $0.03M | $11.87M | $5.50M | $4.41M | $0.00M |
| Gross Profit | $7.92M | ($8.31M) | $0.50M | ($4.41M) | $0.00M |
| Gross Margin %(computed) | 99.66% | -233.86% | 8.34% | — | — |
| Operating Expenses | |||||
| R&D Expenses | $16.73M | $11.89M | $6.04M | $4.94M | $2.54M |
| G&A Expenses | $11.45M | $8.89M | $7.83M | $4.85M | $2.31M |
| Total Operating Expenses | $28.18M | $8.94M | $8.40M | $5.40M | $4.87M |
| Operating Income | ($20.27M) | ($17.25M) | ($7.90M) | ($9.81M) | ($4.87M) |
| Operating Margin %(computed) | -255.05% | -485.35% | -131.67% | — | — |
| Interest Income | $0.00M | $0.00M | $0.00M | $0.00M | $0.00M |
| Interest Expense | $0.00M | $0.00M | $0.00M | $0.00M | $0.00M |
| Income Before Tax | ($21.22M) | ($15.60M) | ($7.26M) | ($12.24M) | ($4.89M) |
| Income Tax Expense | $0.00M | ($0.72M) | $0.72M | $0.00M | $0.00M |
| Net Income | ($21.23M) | ($14.88M) | ($7.99M) | ($12.24M) | ($4.89M) |
| Net Margin %(computed) | -267.14% | -418.70% | -133.08% | — | — |
| Per Share & EBITDA | |||||
| EPS (Basic) | $-1.27 | $-0.98 | $-0.79 | $-1.23 | $-0.74 |
| Wtd Avg Shares | 16.73M | 15.24M | 10.16M | 9.95M | 6.60M |
| EBITDA | ($20.24M) | ($17.20M) | ($7.33M) | ($9.26M) | ($4.85M) |
| EBITDA Margin %(computed) | -254.71% | -483.88% | -122.17% | — | — |
Data source: Financial Modeling Prep · Last updated: 2026-06-09 · USD · M
Explore more Coya Therapeutics, Inc. data
About Coya Therapeutics, Inc. (COYA) Income Statement
Coya Therapeutics, Inc. (COYA) income statement data is sourced from SEC Form 10-K and 10-Q filings. For fiscal year 2025, COYA reported revenue of $0.01B, gross profit of $0.01B (gross margin 99.66%), and net income of ($0.02B) — a net profit margin of -267.14%.
Frequently asked questions
COYA · 4 questionsCoya Therapeutics, Inc. (COYA) reported revenue of $0.01B for 2025, up 123.6% year-over-year.
COYA revenueCOYA salesannual revenue YoYincome statement
· Source: FMP /stable/income-statement · SEC EDGAR Form 10-K & 10-Q · As of 2026-06-09